RAINBOWFISH
E561099
RAINBOWFISH is a clinical trial evaluating risdiplam in infants with spinal muscular atrophy, particularly those pre-symptomatic or very young at treatment initiation.
All labels observed (1)
| Label | Occurrences |
|---|---|
| RAINBOWFISH canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6004786 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: RAINBOWFISH Context triple: [risdiplam, clinicalTrialProgram, RAINBOWFISH]
-
A.
Fishke
Fishke is the titular lame Jewish protagonist of Mendele Mocher Sforim’s classic Yiddish novel "Fishke the Lame," known for its blend of social critique and folk humor.
-
B.
The Fish (Schindleria Praematurus)
The Fish (Schindleria praematurus) is an extremely small, transparent marine fish species known for its larval-like adult form and status as one of the world’s tiniest vertebrates.
-
C.
Poecilia
Poecilia is a genus of small freshwater fish that includes popular aquarium species such as guppies and mollies.
-
D.
Goldfish
Goldfish is a popular snack brand best known for its small, fish-shaped crackers often marketed toward children.
-
E.
Melichthys
Melichthys is a genus of triggerfishes known for their laterally compressed bodies and vibrant coloration, found in tropical and subtropical ocean waters.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: RAINBOWFISH Target entity description: RAINBOWFISH is a clinical trial evaluating risdiplam in infants with spinal muscular atrophy, particularly those pre-symptomatic or very young at treatment initiation.
-
A.
Fishke
Fishke is the titular lame Jewish protagonist of Mendele Mocher Sforim’s classic Yiddish novel "Fishke the Lame," known for its blend of social critique and folk humor.
-
B.
The Fish (Schindleria Praematurus)
The Fish (Schindleria praematurus) is an extremely small, transparent marine fish species known for its larval-like adult form and status as one of the world’s tiniest vertebrates.
-
C.
Poecilia
Poecilia is a genus of small freshwater fish that includes popular aquarium species such as guppies and mollies.
-
D.
Goldfish
Goldfish is a popular snack brand best known for its small, fish-shaped crackers often marketed toward children.
-
E.
Melichthys
Melichthys is a genus of triggerfishes known for their laterally compressed bodies and vibrant coloration, found in tropical and subtropical ocean waters.
- F. None of above. chosen
Statements (30)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
interventional study ⓘ |
| aimsTo | treat spinal muscular atrophy before onset of clinical symptoms ⓘ |
| drugMechanismStudied | increasing SMN protein levels via SMN2 splicing modification ⓘ |
| enrollmentCriteriaIncludes |
genetically confirmed spinal muscular atrophy
ⓘ
very young age at first dose ⓘ |
| evaluates | risdiplam NERFINISHED ⓘ |
| focusesOn |
pre-symptomatic infants with spinal muscular atrophy
ⓘ
very young infants at treatment initiation ⓘ |
| hasIntervention | risdiplam NERFINISHED ⓘ |
| hasPopulation |
infants with spinal muscular atrophy
ⓘ
pre-symptomatic spinal muscular atrophy patients ⓘ very young spinal muscular atrophy patients ⓘ |
| hasPrimaryObjective | to assess efficacy of risdiplam in preventing or delaying symptoms of spinal muscular atrophy in infants ⓘ |
| hasSecondaryObjective | to assess safety and tolerability of risdiplam in infants with spinal muscular atrophy ⓘ |
| investigates |
efficacy of risdiplam in spinal muscular atrophy
ⓘ
safety of risdiplam in spinal muscular atrophy ⓘ |
| phase | Phase II ⓘ |
| relatedTo |
Evrysdi clinical development program
ⓘ
treatment of spinal muscular atrophy type 1 ⓘ |
| routeOfAdministration | oral risdiplam ⓘ |
| sponsor |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| studiesCondition | spinal muscular atrophy NERFINISHED ⓘ |
| studiesDrug | risdiplam (Evrysdi) NERFINISHED ⓘ |
| targetsAgeGroup | infants ⓘ |
| targetsDiseaseStage | pre-symptomatic stage of spinal muscular atrophy ⓘ |
| therapeuticArea |
neuromuscular disease
ⓘ
rare disease ⓘ |
| usesDrugClass | SMN2 splicing modifier ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: RAINBOWFISH Description of subject: RAINBOWFISH is a clinical trial evaluating risdiplam in infants with spinal muscular atrophy, particularly those pre-symptomatic or very young at treatment initiation.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.